Thus, MDS patients show a specific systemic chemokine profile that at least partially overlaps with the AML profile (CCL2/3/4/5, CXCL8/10; see Table 2) and the use of chemokine profiling may be relevant for the prognostic classification of these patients. This evidence concerns the gene CCL2 and myelodysplastic syndrome.